Jan 03, 2023
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Dec 22, 2022
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Dec 07, 2022
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Dec 05, 2022
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Dec 01, 2022
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
